½ÃÀ庸°í¼­
»óǰÄÚµå
1683255

¼¼°èÀÇ RWE(Real World Evidence) ¼Ö·ç¼Ç ½ÃÀå Á¶»ç º¸°í¼­ : »ê¾÷ ºÐ¼®, ±Ô¸ð, Á¡À¯À², ¼ºÀå, µ¿Çâ, ¿¹Ãø(2025-2033³â)

Global Real World Evidence Solutions Market Research Report- Industry Analysis, Size, Share, Growth, Trends and Forecast 2025 to 2033

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Value Market Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 152 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ RWE(Real World Evidence) ¼Ö·ç¼Ç ½ÃÀå ±Ô¸ð´Â 2024³â 33¾ï 7,000¸¸ ´Þ·¯¿¡¼­ 2033³â¿¡´Â 72¾ï 9,000¸¸ ´Þ·¯·Î ¼ºÀåÇϸç, 2026-2033³âÀÇ ¿¹Ãø ±â°£ Áß 8.93%ÀÇ °ß°íÇÑ ¿¬Æò±Õ ¼ºÀå·ü(CAGR)À» º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°è ¸®¾ó¿ùµå¿¡ºñ´ø½º(RWE) ¼Ö·ç¼Ç ½ÃÀåÀº ÀÇ·á ÀÇ»ç°áÁ¤¿¡ ÀÖÀ¸¸ç, µ¥ÀÌÅͺ£À̽º ÀλçÀÌÆ®¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿¡ ÈûÀÔ¾î Å« ÆøÀÇ ¼ºÀå¼¼¸¦ º¸ÀÏ °ÍÀ¸·Î Àü¸ÁµË´Ï´Ù. ¸»ÇÕ´Ï´Ù. Á¦¾à»ç, ÁöºÒÀÚ, ±ÔÁ¦±â°üÀ» Æ÷ÇÔÇÑ ÀÇ·á »ýŰè ÀÌÇØ°ü°èÀÚµéÀÌ Ä¡·áÀÇ È¿°ú¿Í ¾ÈÀü¼º¿¡ ´ëÇÑ ÀÌÇØ¸¦ ³ôÀ̱â À§ÇØ ³ë·ÂÇϸ鼭 RWE ¼Ö·ç¼ÇÀÇ Ã¤ÅÃÀÌ Å©°Ô Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ·¯ÇÑ Ãß¼¼´Â °¡Ä¡ ±â¹Ý Áø·á¿¡ ´ëÇÑ Á߿伺ÀÌ ³ô¾ÆÁö°í ÀÖÀ¸¸ç, »óȯ °áÁ¤¿¡ Á¤º¸¸¦ Á¦°øÇϱâ À§ÇÑ Áõ°ÅÀÇ Çʿ伺¿¡ ÀÇÇØ ´õ¿í Áö¿øµÇ°í ÀÖ½À´Ï´Ù.

¶ÇÇÑ µ¥ÀÌÅÍ ºÐ¼®°ú ±â¼úÀÇ ¹ßÀüÀº RWE ¼Ö·ç¼ÇÀÇ Àü¸ÁÀ» º¯È­½Ãų °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ºòµ¥ÀÌÅÍ, ¸Ó½Å·¯´×, ÀΰøÁö´ÉÀÇ ÅëÇÕÀº ¹æ´ëÇÑ ¾çÀÇ ½ÇÁ¦ µ¥ÀÌÅ͸¦ ºÐ¼®ÇÒ ¼ö ÀÖ´Â ´É·ÂÀ» °­È­ÇÏ¿© ÀÓ»ó ½Ç½À ¹× Á¶Ä¡¿¡ Á¤º¸¸¦ Á¦°øÇÒ ¼ö ÀÖ´Â ½Ç¿ëÀûÀÎ ÀλçÀÌÆ®¸¦ Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ ÀüÀÚÀǹ«±â·Ï°ú ȯÀÚ µî·ÏÀÇ È°¿ëµµ°¡ ³ô¾ÆÁü¿¡ µû¶ó ¾çÁúÀÇ µ¥ÀÌÅÍ ¼öÁýÀÌ ¿ëÀÌÇØÁ® RWE ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ ´õ¿í Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÇ·á ±â°üµéÀÌ ÀÓ»ó ¹× »ó¾÷Àû Àü·«À» Áö¿øÇÏ´Â RWE(Real World Evidence)ÀÇ °¡Ä¡¸¦ Á¡Á¡ ´õ ¸¹ÀÌ ÀνÄÇÔ¿¡ µû¶ó ½ÃÀåÀº ÀÌ·¯ÇÑ ¿ä±¸¸¦ ÃæÁ·½ÃŰ´Â Çõ½ÅÀûÀÎ ¼Ö·ç¼ÇÀÇ ±Þ°ÝÇÑ Áõ°¡¸¦ ¸ñ°ÝÇÒ ¼ö ÀÖÀ» °ÍÀÔ´Ï´Ù.

¶ÇÇÑ È¯ÀÚ Âü¿©¿¡ ´ëÇÑ °ü½É Áõ°¡¿Í ȯÀÚ º¸°í °á°úÀÇ Á߿伺Àº RWE ¼Ö·ç¼Ç ½ÃÀåÀÇ ¹Ì·¡¸¦ Çü¼ºÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ȯÀÚ°¡ ÀÇ·á ÀÇ»ç°áÁ¤¿¡ Âü¿©ÇÔ¿¡ µû¶ó ȯÀÚÀÇ °æÇè°ú °á°ú¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖ´Â ¼Ö·ç¼ÇÀÇ Çʿ伺ÀÌ Á¡Á¡ ´õ Ä¿Áö°í ÀÖ½À´Ï´Ù. ȯÀÚÀÇ °üÁ¡À» ¹Ý¿µÇÑ RWE ¼Ö·ç¼ÇÀº Ä¡·á È¿°ú¿¡ ´ëÇÑ º¸´Ù Á¾ÇÕÀûÀÎ ÀÌÇØ¸¦ ÅëÇØ ±Ã±ØÀûÀ¸·Î ȯÀÚ Ä¡·á¸¦ °³¼±ÇÒ ¼ö ÀÖÀ¸¸ç, RWE ¼Ö·ç¼Ç ½ÃÀåÀÌ Áõ°Å ±â¹Ý ÀÇ·áÀÇ ÃÖÀü¼±¿¡ ¼­±â À§Çؼ­´Â µ¥ÀÌÅÍ ÇÁ·Î¹ÙÀÌ´õ, ÀÇ·á ±â°ü, ±ÔÁ¦±â°üÀÇ Çù·ÂÀÌ ÇʼöÀûÀÔ´Ï´Ù. ÇʼöÀûÀÔ´Ï´Ù.

´ç»çÀÇ º¸°í¼­´Â °í°´¿¡°Ô ´Ù¾çÇÑ »ê¾÷ ¹× ½ÃÀå¿¡ ´ëÇÑ Á¾ÇÕÀûÀÌ°í ½Ç¿ëÀûÀÎ ÀλçÀÌÆ®¸¦ Á¦°øÇϱâ À§ÇØ ¼¼½ÉÇÏ°Ô ÀÛ¼ºµÇ¾ú½À´Ï´Ù. °¢ º¸°í¼­´Â ½ÃÀå »óȲÀ» ¿ÏÀüÈ÷ ÀÌÇØÇϱâ À§ÇØ ¸î °¡Áö Áß¿äÇÑ ¿ä¼Ò¸¦ Æ÷ÇÔÇϰí ÀÖ½À´Ï´Ù.

½ÃÀå °³¿ä : Á¤ÀÇ, ºÐ·ù, »ê¾÷ ÇöȲ µî ½ÃÀå¿¡ ´ëÇÑ ÀÚ¼¼ÇÑ ¼Ò°³.

½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ : ½ÃÀå ¼ºÀå¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ÁÖ¿ä ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ ¹× °úÁ¦¸¦ »ó¼¼ÇÏ°Ô ºÐ¼®ÇÕ´Ï´Ù. ÀÌ ¼½¼Ç¿¡¼­´Â ±â¼ú ¹ßÀü, ±ÔÁ¦ º¯È­, »õ·Î¿î µ¿Çâ µîÀÇ ¿äÀÎÀ» °ËÅäÇÕ´Ï´Ù.

¼¼ºÐÈ­ ºÐ¼® : Á¦Ç° À¯Çü, ¾ÖÇø®ÄÉÀ̼Ç, ÃÖÁ¾»ç¿ëÀÚ, Áö¿ª µîÀÇ ±âÁØ¿¡ µû¶ó ½ÃÀåÀ» ¸íÈ®ÇÑ ºÎ¹®À¸·Î ºÐ·ùÇÕ´Ï´Ù. ÀÌ ºÐ¼®À» ÅëÇØ °¢ ºÎ¹®ÀÇ ¼º°ú¿Í ÀáÀç·ÂÀ» ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù.

°æÀï»óȲ : ½ÃÀå Á¡À¯À², Á¦Ç° Æ÷Æ®Æú¸®¿À, Àü·«Àû ±¸»ó, À繫½ÇÀû µî ÁÖ¿ä ½ÃÀå ÁøÀÔ±â¾÷¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ Æò°¡. ÁÖ¿ä ±â¾÷ÀÌ Ã¤ÅÃÇϰí ÀÖ´Â °æÀï ¿ªÇÐ ¹× ÁÖ¿ä Àü·«¿¡ ´ëÇÑ ÀλçÀÌÆ®ÀÌ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù.

½ÃÀå ¿¹Ãø : °ú°Å µ¥ÀÌÅÍ¿Í ÇöÀç ½ÃÀå »óȲÀ» ¹ÙÅÁÀ¸·Î ÀÏÁ¤ ±â°£ Áß ½ÃÀå ±Ô¸ð¿Í ¼ºÀå Ãß¼¼¸¦ ¿¹ÃøÇÕ´Ï´Ù. ¿©±â¿¡´Â Á¤·®Àû ºÐ¼®°ú ¹Ì·¡ ½ÃÀå ±ËÀûÀ» ³ªÅ¸³»´Â ±×·¡ÇÁ Ç¥½Ã°¡ Æ÷ÇԵ˴ϴÙ.

Áö¿ª ºÐ¼® : Áö¿ªº° ½ÃÀå ¼º°ú¸¦ Æò°¡Çϰí ÁÖ¿ä ½ÃÀå ¹× Áö¿ª µ¿ÇâÀ» ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù. Áö¿ª ½ÃÀå ¿ªÇÐ ¹× ºñÁî´Ï½º ±âȸ¸¦ ÀÌÇØÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù.

»õ·Î¿î µ¿Çâ°ú ±âȸ : ÇöÀç ½ÃÀå µ¿Çâ°ú »õ·Î¿î ½ÃÀå µ¿Çâ, ±â¼ú Çõ½Å, ÀáÀçÀû ÅõÀÚ ´ë»ó ºÎ¹®À» ½Äº°ÇÕ´Ï´Ù. ¹Ì·¡ ½ÃÀå °³¹ß ¹× ¼ºÀå Àü¸Á¿¡ ´ëÇÑ ÀλçÀÌÆ®¸¦ Á¦°øÇÕ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå °³¿ä

  • ½ÃÀåÀÇ ÇÏÀ̶óÀÌÆ®
  • ¼¼°è ½ÃÀå ½º³À¼ô

Á¦3Àå RWE(Real World Evidence) ¼Ö·ç¼Ç »ê¾÷ ºÐ¼®

  • ¼­·Ð : ½ÃÀå ¿ªÇÐ
  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
  • ±âȸ
  • »ê¾÷ µ¿Çâ
  • Porter's Five Forces ºÐ¼®
  • ½ÃÀåÀÇ ¸Å·Â ºÐ¼®

Á¦4Àå ¹ë·ùüÀÎ ºÐ¼®

  • ¹ë·ùüÀÎ ºÐ¼®
  • ¿ø·á ºÐ¼®
    • ¿ø·á ¸®½ºÆ®
    • ¿ø·á Á¦Á¶¾÷ü ¸®½ºÆ®
    • ÁÖ¿ä ¿ø·áÀÇ °¡°Ý µ¿Çâ
  • ÀáÀçÀû ¹ÙÀÌ¾î ¸®½ºÆ®
  • ¸¶ÄÉÆÃ Ã¤³Î
    • Á÷Á¢ ¸¶ÄÉÆÃ
    • °£Á¢ ¸¶ÄÉÆÃ
    • ¸¶ÄÉÆÃ Ã¤³Î ¹ßÀü µ¿Çâ

Á¦5Àå ¼¼°èÀÇ RWE(Real World Evidence) ¼Ö·ç¼Ç ½ÃÀå ºÐ¼® : ÄÄÆ÷³ÍÆ®º°

  • ÄÄÆ÷³ÍÆ®º° °³¿ä
  • ÄÄÆ÷³ÍÆ®º° °ú°Å¡¤¿¹Ãø µ¥ÀÌÅÍ ºÐ¼®
  • ¼­ºñ½º
  • µ¥ÀÌÅͼ¼Æ®

Á¦6Àå ¼¼°èÀÇ RWE(Real World Evidence) ¼Ö·ç¼Ç ½ÃÀå ºÐ¼® : ¿ëµµº°

  • ¿ëµµº° °³¿ä
  • ¿ëµµº° °ú°Å¡¤¿¹Ãø µ¥ÀÌÅÍ ºÐ¼®
  • ÀǾàǰ °³¹ß¡¤½ÂÀÎ
  • ÀÇ·á±â±âÀÇ °³¹ß°ú ½ÂÀÎ
  • »óȯ/º¸Çè Àû¿ë°ú ±ÔÁ¦»ó ÀÇ»ç°áÁ¤
  • ½ÃÆÇÈÄ ¾ÈÀü¼º°ú À¯ÇØ»ç·Ê ¸ð´ÏÅ͸µ

Á¦7Àå ¼¼°èÀÇ RWE(Real World Evidence) ¼Ö·ç¼Ç ½ÃÀå ºÐ¼® : ÃÖÁ¾ ¿ëµµº°

  • ÃÖÁ¾ ¿ëµµº° °³¿ä
  • ÃÖÁ¾ ¿ëµµº° °ú°Å¡¤¿¹Ãø µ¥ÀÌÅÍ ºÐ¼®
  • ÀÇ·á ±â¾÷(Á¦¾à, ¹ÙÀÌ¿ÀÀǾàǰ, ÀÇ·á±â±â)
  • ÀÇ·á »ç¾÷ÀÚ
  • ÀÇ·á ÇÁ·Î¹ÙÀÌ´õ
  • ±âŸ

Á¦8Àå ¼¼°èÀÇ RWE(Real World Evidence) ¼Ö·ç¼Ç ½ÃÀå ºÐ¼® : Ä¡·á ºÎ¹®º°

  • Ä¡·á ¿µ¿ªº° °³¿ä
  • Ä¡·á ¿µ¿ªº° °ú°Å¡¤¿¹Ãø µ¥ÀÌÅÍ ºÐ¼®
  • Á¾¾çÇÐ
  • ¼øÈ¯±â
  • ½Å°æÇÐ
  • ´ç´¢º´
  • Á¤½Å°ú
  • È£Èí±â°ú
  • ±âŸ

Á¦9Àå ¼¼°èÀÇ RWE(Real World Evidence) ¼Ö·ç¼Ç ½ÃÀå ºÐ¼® : Áö¿ªº°

  • Áö¿ªº° Àü¸Á
  • ¼­·Ð
  • ºÏ¹Ì ÆÇ¸Å ºÐ¼®
    • °³¿ä, ½ÇÀû°ú ¿¹Ãø
    • ºÏ¹Ì : ºÎ¹®º°
    • ºÏ¹Ì : ±¹°¡º°
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
  • À¯·´ ÆÇ¸Å ºÐ¼®
    • °³¿ä, ½ÇÀû°ú ¿¹Ãø
    • À¯·´ : ºÎ¹®º°
    • À¯·´ : ±¹°¡º°
    • ¿µ±¹
    • ÇÁ¶û½º
    • µ¶ÀÏ
    • ÀÌÅ»¸®¾Æ
    • ·¯½Ã¾Æ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç ÆÇ¸Å ºÐ¼®
    • °³¿ä, ½ÇÀû°ú ¿¹Ãø
    • ¾Æ½Ã¾ÆÅÂÆò¾ç : ºÎ¹®º°
    • ¾Æ½Ã¾ÆÅÂÆò¾ç : ±¹°¡º°
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • Çѱ¹
    • È£ÁÖ
    • µ¿³²¾Æ½Ã¾Æ
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä« ÆÇ¸Å ºÐ¼®
    • °³¿ä, ½ÇÀû°ú ¿¹Ãø
    • ¶óƾ¾Æ¸Þ¸®Ä« : ºÎ¹®º°
    • ¶óƾ¾Æ¸Þ¸®Ä« : ±¹°¡º°
    • ºê¶óÁú
    • ¾Æ¸£ÇîÆ¼³ª
    • Æä·ç
    • Ä¥·¹
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« ÆÇ¸Å ºÐ¼®
    • °³¿ä, ½ÇÀû°ú ¿¹Ãø
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ºÎ¹®º°
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ±¹°¡º° ¸®½ºÆ®
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®
    • À̽º¶ó¿¤
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦10Àå RWE(Real World Evidence) ¼Ö·ç¼Ç ±â¾÷ÀÇ °æÀï ±¸µµ

  • RWE(Real World Evidence) ¼Ö·ç¼Ç ½ÃÀå °æÀï
  • Á¦ÈÞ¡¤Çù¾÷¡¤°è¾à
  • ÇÕº´¡¤Àμö
  • ½ÅÁ¦Ç° ¹ß¸Å
  • ±âŸ °³¹ß

Á¦11Àå ±â¾÷ °³¿ä

  • »óÀ§ ±â¾÷ÀÇ ½ÃÀå Á¡À¯À² ºÐ¼®
  • ½ÃÀå ÁýÁßµµ
  • IQVIA Inc.
  • IBM
  • PPD Inc.(Thermo Fisher Scientific Inc.°¡ Àμö)
  • Parexel International(MA) Corporation
  • PerkinElmer Inc.
  • ICON Plc
  • Oracle
  • Syneos Health
  • Cegedim Health Data
  • Medpace
KSA 25.04.22

Global Real World Evidence Solutions Market size is anticipated to grow from USD 3.37 Billion in 2024 to USD 7.29 Billion by 2033, showcasing a robust Compound Annual Growth Rate (CAGR) of 8.93% during the forecast period of 2026 to 2033.

The global real-world evidence (RWE) solutions market is set to witness substantial growth, driven by the increasing demand for data-driven insights in healthcare decision-making. RWE refers to the clinical evidence derived from the analysis of real-world data, which includes information on patient health status and the delivery of healthcare. As stakeholders in the healthcare ecosystem, including pharmaceutical companies, payers, and regulatory agencies, seek to enhance the understanding of treatment effectiveness and safety, the adoption of RWE solutions is expected to rise significantly. This trend is further supported by the growing emphasis on value-based care and the need for evidence to inform reimbursement decisions.

Moreover, advancements in data analytics and technology are anticipated to transform the RWE solutions landscape. The integration of big data, machine learning, and artificial intelligence is enhancing the ability to analyze vast amounts of real-world data, providing actionable insights that can inform clinical practice and policy. Additionally, the increasing availability of electronic health records and patient registries is facilitating the collection of high-quality data, further driving the demand for RWE solutions. As healthcare organizations increasingly recognize the value of real-world evidence in supporting clinical and commercial strategies, the market is likely to witness a surge in innovative solutions that cater to these needs.

In addition, the growing focus on patient engagement and the importance of patient-reported outcomes are expected to shape the future of the RWE solutions market. As patients become more involved in their healthcare decisions, the need for solutions that capture their experiences and outcomes is becoming increasingly important. RWE solutions that incorporate patient perspectives can provide a more comprehensive understanding of treatment impact, ultimately leading to improved patient care. Collaborative efforts between data providers, healthcare organizations, and regulatory bodies will be essential in driving these advancements, ensuring that the RWE solutions market remains at the forefront of evidence-based healthcare.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

SEGMENTATION COVERED IN THE REPORT

By Component

  • Services
  • Data Sets

By Application

  • Drug Development & Approvals
  • Medical Device Development & Approvals
  • Reimbursement/Coverage and Regulatory Decision Making
  • Post Market Safety & Adverse Events Monitoring

By End-use

  • Healthcare Companies (Pharmaceutical, Biopharmaceutical, Medical Device)
  • Healthcare Payers
  • Healthcare Providers
  • Others

By Therapeutic Area

  • Oncology
  • Cardiology
  • Neurology
  • Diabetes
  • Psychiatry
  • Respiratory
  • Others
  • COMPANIES PROFILED
  • IQVIA Inc.
  • IBM
  • PPD Inc. (acquired by Thermo Fisher Scientific Inc.)
  • Parexel International (MA) Corporation
  • PerkinElmer Inc.
  • ICON plc
  • Oracle
  • Syneos Health
  • Cegedim Health Data
  • Medpace.
  • The above list can be customized.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Report Description
    • 1.1.1 Objective
    • 1.1.2 Target Audience
    • 1.1.3 Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1 Market Research Process
    • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3. REAL WORLD EVIDENCE SOLUTIONS INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Component
    • 3.7.2 Market Attractiveness Analysis By Application
    • 3.7.3 Market Attractiveness Analysis By End-use
    • 3.7.4 Market Attractiveness Analysis By Therapeutic Area
    • 3.7.5 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1 List of Raw Materials
    • 4.2.2 Raw Material Manufactures List
    • 4.2.3 Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1 Direct Marketing
    • 4.4.2 Indirect Marketing
    • 4.4.3 Marketing Channel Development Trend

5. GLOBAL REAL WORLD EVIDENCE SOLUTIONS MARKET ANALYSIS BY COMPONENT

  • 5.1. Overview By Component
  • 5.2. Historical and Forecast Data Analysis By Component
  • 5.3. Services Historic and Forecast Sales By Regions
  • 5.4. Data Sets Historic and Forecast Sales By Regions

6. GLOBAL REAL WORLD EVIDENCE SOLUTIONS MARKET ANALYSIS BY APPLICATION

  • 6.1. Overview By Application
  • 6.2. Historical and Forecast Data Analysis By Application
  • 6.3. Drug Development & Approvals Historic and Forecast Sales By Regions
  • 6.4. Medical Device Development & Approvals Historic and Forecast Sales By Regions
  • 6.5. Reimbursement/Coverage and Regulatory Decision Making Historic and Forecast Sales By Regions
  • 6.6. Post Market Safety & Adverse Events Monitoring Historic and Forecast Sales By Regions

7. GLOBAL REAL WORLD EVIDENCE SOLUTIONS MARKET ANALYSIS BY END-USE

  • 7.1. Overview By End-use
  • 7.2. Historical and Forecast Data Analysis By End-use
  • 7.3. Healthcare Companies (Pharmaceutical, Biopharmaceutical, Medical Device) Historic and Forecast Sales By Regions
  • 7.4. Healthcare Payers Historic and Forecast Sales By Regions
  • 7.5. Healthcare Providers Historic and Forecast Sales By Regions
  • 7.6. Others Historic and Forecast Sales By Regions

8. GLOBAL REAL WORLD EVIDENCE SOLUTIONS MARKET ANALYSIS BY THERAPEUTIC AREA

  • 8.1. Overview By Therapeutic Area
  • 8.2. Historical and Forecast Data Analysis By Therapeutic Area
  • 8.3. Oncology Historic and Forecast Sales By Regions
  • 8.4. Cardiology Historic and Forecast Sales By Regions
  • 8.5. Neurology Historic and Forecast Sales By Regions
  • 8.6. Diabetes Historic and Forecast Sales By Regions
  • 8.7. Psychiatry Historic and Forecast Sales By Regions
  • 8.8. Respiratory Historic and Forecast Sales By Regions
  • 8.9. Others Historic and Forecast Sales By Regions

9. GLOBAL REAL WORLD EVIDENCE SOLUTIONS MARKET ANALYSIS BY GEOGRAPHY

  • 9.1. Regional Outlook
  • 9.2. Introduction
  • 9.3. North America Sales Analysis
    • 9.3.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.3.2 North America By Segment Sales Analysis
    • 9.3.3 North America By Country Sales Analysis
    • 9.3.4 United States Sales Analysis
    • 9.3.5 Canada Sales Analysis
    • 9.3.6 Mexico Sales Analysis
  • 9.4. Europe Sales Analysis
    • 9.4.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.4.2 Europe By Segment Sales Analysis
    • 9.4.3 Europe By Country Sales Analysis
    • 9.4.4 United Kingdom Sales Analysis
    • 9.4.5 France Sales Analysis
    • 9.4.6 Germany Sales Analysis
    • 9.4.7 Italy Sales Analysis
    • 9.4.8 Russia Sales Analysis
    • 9.4.9 Rest Of Europe Sales Analysis
  • 9.5. Asia Pacific Sales Analysis
    • 9.5.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.5.2 Asia Pacific By Segment Sales Analysis
    • 9.5.3 Asia Pacific By Country Sales Analysis
    • 9.5.4 China Sales Analysis
    • 9.5.5 India Sales Analysis
    • 9.5.6 Japan Sales Analysis
    • 9.5.7 South Korea Sales Analysis
    • 9.5.8 Australia Sales Analysis
    • 9.5.9 South East Asia Sales Analysis
    • 9.5.10 Rest Of Asia Pacific Sales Analysis
  • 9.6. Latin America Sales Analysis
    • 9.6.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.6.2 Latin America By Segment Sales Analysis
    • 9.6.3 Latin America By Country Sales Analysis
    • 9.6.4 Brazil Sales Analysis
    • 9.6.5 Argentina Sales Analysis
    • 9.6.6 Peru Sales Analysis
    • 9.6.7 Chile Sales Analysis
    • 9.6.8 Rest of Latin America Sales Analysis
  • 9.7. Middle East & Africa Sales Analysis
    • 9.7.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.7.2 Middle East & Africa By Segment Sales Analysis
    • 9.7.3 Middle East & Africa By Country Sales Analysis
    • 9.7.4 Saudi Arabia Sales Analysis
    • 9.7.5 UAE Sales Analysis
    • 9.7.6 Israel Sales Analysis
    • 9.7.7 South Africa Sales Analysis
    • 9.7.8 Rest Of Middle East And Africa Sales Analysis

10. COMPETITIVE LANDSCAPE OF THE REAL WORLD EVIDENCE SOLUTIONS COMPANIES

  • 10.1. Real World Evidence Solutions Market Competition
  • 10.2. Partnership/Collaboration/Agreement
  • 10.3. Merger And Acquisitions
  • 10.4. New Product Launch
  • 10.5. Other Developments

11. COMPANY PROFILES OF REAL WORLD EVIDENCE SOLUTIONS INDUSTRY

  • 11.1. Top Companies Market Share Analysis
  • 11.2. Market Concentration Rate
  • 11.3. IQVIA Inc.
    • 11.3.1 Company Overview
    • 11.3.2 Company Revenue
    • 11.3.3 Products
    • 11.3.4 Recent Developments
  • 11.4. IBM
    • 11.4.1 Company Overview
    • 11.4.2 Company Revenue
    • 11.4.3 Products
    • 11.4.4 Recent Developments
  • 11.5. PPD Inc. (Acquired By Thermo Fisher Scientific Inc.)
    • 11.5.1 Company Overview
    • 11.5.2 Company Revenue
    • 11.5.3 Products
    • 11.5.4 Recent Developments
  • 11.6. Parexel International (MA) Corporation
    • 11.6.1 Company Overview
    • 11.6.2 Company Revenue
    • 11.6.3 Products
    • 11.6.4 Recent Developments
  • 11.7. PerkinElmer Inc.
    • 11.7.1 Company Overview
    • 11.7.2 Company Revenue
    • 11.7.3 Products
    • 11.7.4 Recent Developments
  • 11.8. ICON Plc
    • 11.8.1 Company Overview
    • 11.8.2 Company Revenue
    • 11.8.3 Products
    • 11.8.4 Recent Developments
  • 11.9. Oracle
    • 11.9.1 Company Overview
    • 11.9.2 Company Revenue
    • 11.9.3 Products
    • 11.9.4 Recent Developments
  • 11.10. Syneos Health
    • 11.10.1 Company Overview
    • 11.10.2 Company Revenue
    • 11.10.3 Products
    • 11.10.4 Recent Developments
  • 11.11. Cegedim Health Data
    • 11.11.1 Company Overview
    • 11.11.2 Company Revenue
    • 11.11.3 Products
    • 11.11.4 Recent Developments
  • 11.12. Medpace
    • 11.12.1 Company Overview
    • 11.12.2 Company Revenue
    • 11.12.3 Products
    • 11.12.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies

ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦